K&S Partners 11 Partners Recognized Among WIPR Leaders 2025
K&S Partners is proud to announce that 11 its Partners have been recognized as WIPR Leaders 2025 by World IP Review (WIPR). This distinguished list honors leading intellectual property practitioners around the globe for their contributions, expertise, and influence in the...
Managing IP recognises K&S Partner’s’ Trade Mark Practice and Five Partners as IP Stars
K&S Partners has been recognized in Managing IP’s 2025 IP Stars guide for its outstanding Intellectual Property work, securing Tier 1 rankings in Trade Mark practice, and celebrating five of its leading practitioners for their continued “star” status in patent and trademark...
Dr. Reddy’s secures early win in Novo Nordisk’s ‘Ozempic’ infringement claim
On May 29, the Delhi High Court recorded Dr. Reddy’s undertaking not to sell its Ozempic-like drug in India, amid Novo Nordisk’s ongoing patent suit. Dr. Reddy’s noted it holds a manufacturing licence but reserves the right to export to non-patent jurisdictions—an argument opposed by Novo...
Beyond Boundaries – A Chat On The Ordinary And Unusual IP: Podcast featuring Latha R Nair
Latha R Nair was featured in an insightful podcast by The Emerging India Forum where she discusses her journey – from protecting the legacy of India’s most cherished Geographical Indications to untangling copyright issues in a digital world, with Lion Amirr...
Delhi High Court grants interim relief to luggage brand Mokobara in trademark case
Bar and Bench covers K&S Partners’ recent success in representing luggage brand Mokobara, securing interim relief from the Delhi High Court in a hashtag#trademark infringement case. The Court found a strong prima facie case against the defendants selling suitcases bearing a virtually identical trade mark and trade dress as that of...
Dr. Reddy’s secures early win in Novo Nordisk’s ‘Ozempic’ infringement claim
Managing IP has covered the ongoing patent dispute between Novo Nordisk (represented by K&S Partners) and Dr. Reddy’s over semaglutide (Ozempic). While the Delhi High Court has declined interim relief at this stage, the case is still in its early phases and will continue to be heard in...
K&S Partners Recognized in IAM Patent 1000: The World’s Leading Patent Professionals 2025
K&S Partners is proud to announce its inclusion in the IAM Patent 1000: The World’s Leading Patent Professionals 2025 edition, reinforcing our position as a top-tier intellectual property firm in India.
K&S Partners has been ranked Gold for Patent Litigation and Highly Recommended for Patent Prosecution in...
Highlights of the Indian Biological Diversity Regulations, 2025⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀
The National Biodiversity Authority (NBA) on 29th April 2025, issued the Biological Diversity Regulations, 2025 known as the “Access to Biological Resources and Knowledge Associated thereto and Fair and Equitable Sharing of Benefits” (“Regulations”), to implement the revised Biological Diversity (BD) Act (2023) and Rules...
K&S Partners recognized in IBLJ Indian Law Firm Awards 2025 for Intellectual Property Protection
Recognized for its Intellectual Property (IP) expertise, K&S Partners has been named in IBLJ’s 2025 Indian Law Firm Awards.
K&S Partners has been recognized by India Business Law Journal (IBLJ) as a leading firm in theIndian Law Firm Awards 2025 for excellence in Intellectual Property Protection. This marks...
K&S Partners Named Among India’s Top 10 Trademark and IP Law Firms for 2025
K&S Partners is proud to be recognized among India’s “Top 10 Trademark Firms and IP Practices” by The Trademark Lawyer magazine for the year, 2025. This prestigious ranking is based on the publication’s rigorous research methodology, which evaluates factors such as client feedback, peer recommendations, notable case outcomes, and market...